Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

127.40
Delayed Data
As of Jul 21
 -1.26 / -0.98%
Today’s Change
96.63
Today|||52-Week Range
177.93
+17.26%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$3.2B

Company Description

Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Contact Information

Intercept Pharmaceuticals, Inc.
450 West 15th Street
New York New York 10011
P:(646) 747-1000
Investor Relations:

Employees

Shareholders

Mutual fund holders57.05%
Individual stakeholders36.33%
Other institutional28.53%

Top Executives

Mark E. PruzanskiPresident, Chief Executive Officer & Director
Jerome B. DursoChief Operating Officer
Sandip S. KapadiaChief Financial Officer
David A. ShapiroChief Medical Officer & Executive VP-Development
Rachel L. McMinnChief Business & Strategy Officer